The European Medicines Agency intends to revise its guideline on gene therapy medicinal products dealing with quality, non-clinical and clinical aspects to address issues in this “rapidly developing field”1.
The current guideline, says the EMA, does not address some of the issues that have emerged since it was adopted in 20012...
Please login to read the full article.
